Skip to content
DataLookout
Menu

NCT07929051

A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Occurrence of treatment-emergent adverse events ( AEs) during the on-treatment period.
Timeframe: Up to 36 months

Secondary (1)

Obrixtamig treatment duration from the first administration in parent trial until the last administration in rollover trial.

Arms and interventions

Rollover armExperimental

Patients who have previously received treatment with obrixtamig in another Boehringer Ingelheim-sponsored clinical trial (referred to as the 'parent trial') will be enrolled in this rollover study. Treatment schedule and doses in the parent study will be continued in the rollover study.

Biologicals: Obrixtamig, Ezabenlimab, Atezolizumab, Tocilizumab

Drugs: Topotecan

Sites

15 sites in 6 countries

France 5, Germany 3, Japan 2, Poland 2, Spain 2, Belgium 1